We are live on ! Find out more
KERX

Keryx Biopharmaceuticals Inc
KERX

Delisted

KERX was delisted on the 12th of December, 2018.

150 hedge funds and large institutions have $1.14B invested in Keryx Biopharmaceuticals Inc in 2014 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 52 increasing their positions, 44 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

173% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 15

73% more capital invested

Capital invested by funds: $660M → $1.14B (+$484M)

21% more funds holding

Funds holding: 124150 (+26)

18% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 44

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

12% more call options, than puts

Call options by funds: $32.6M | Put options by funds: $29.1M

Holders
150
Holders Change
+26
Holders Change %
+20.97%
% of All Funds
4.33%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.2%
New
41
Increased
52
Reduced
44
Closed
15
Calls
$32.6M
Puts
$29.1M
Net Calls
+$3.44M
Net Calls Change
-$4.51M
Name Holding Trade Value Shares
Change
Change in
Stake
Dimensional Fund Advisors
76
Dimensional Fund Advisors
Texas
$1.55M -$103K -6,800 -7%
ProShare Advisors
77
ProShare Advisors
Maryland
$1.54M +$1.36M +90,330 New
RhumbLine Advisers
78
RhumbLine Advisers
Massachusetts
$1.45M +$78.9K +5,230 +7%
SGAM
79
Smith Group Asset Management
Texas
$1.4M +$1.24M +82,100 New
HCMT
80
Highland Capital Management (Texas)
Texas
$1.36M +$813K +53,895 +206%
QIM
81
Quantitative Investment Management
Virginia
$1.34M +$1.19M +78,800 New
Deutsche Bank
82
Deutsche Bank
Germany
$1.26M -$203K -13,472 -15%
D.E. Shaw & Co
83
D.E. Shaw & Co
New York
$1.25M -$9.69M -641,932 -90%
MLICM
84
Metropolitan Life Insurance Company (MetLife)
New York
$1.23M +$99.8K +6,612 +10%
American Century Companies
85
American Century Companies
Missouri
$1.21M -$78.9K -5,230 -7%
PPA
86
Parametric Portfolio Associates
Washington
$1.2M +$22.3K +1,477 +2%
SO
87
STRS Ohio
Ohio
$1.15M -$192K -12,700 -16%
AIG
88
American International Group
New York
$1.06M +$46.7K +3,094 +5%
State Board of Administration of Florida Retirement System
89
State Board of Administration of Florida Retirement System
Florida
$954K
VOYA Investment Management
90
VOYA Investment Management
Georgia
$932K
MIM
91
Marco Investment Management
Georgia
$899K +$22.6K +1,500 +3%
Goldman Sachs
92
Goldman Sachs
New York
$873K -$7.76M -514,373 -91%
HPA
93
Hilltop Park Associates
New York
$852K -$754K -50,000 -50%
NFC
94
Northeast Financial Consultants
Connecticut
$823K -$55.8K -3,700 -7%
SG Americas Securities
95
SG Americas Securities
New York
$784K +$554K +36,752 +397%
GH
96
GAM Holding
Switzerland
$750K +$664K +44,000 New
Schroder Investment Management Group
97
Schroder Investment Management Group
United Kingdom
$702K +$621K +41,191 New
EMG
98
Ellington Management Group
Connecticut
$697K +$617K +40,900 New
CCM
99
Cadence Capital Management
Massachusetts
$683K +$605K +40,110 New
BG
100
BlackRock Group
United Kingdom
$624K +$97K +6,429 +21%

KERX Hedge Fund Activity: Q1 2014 in Review

150 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q1 2014, worth a combined $1.14B — up 73% from $660M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new KERX positions and 15 closed out — a net gain of 26 holders — while 52 added to existing stakes and 44 trimmed.

The largest buyer was Baupost Group, opening a new position worth an estimated $95.2M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $22M sold.

  • 150 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q1 2014, up from 124 in Q4 2013.
  • Funds reported $1.14B of Keryx Biopharmaceuticals Inc stock for Q1 2014, up 73% quarter-over-quarter.
  • 41 funds opened new Keryx Biopharmaceuticals Inc positions in Q1 2014 and 15 closed out, a net change of +26 holders.
  • The largest Keryx Biopharmaceuticals Inc buyer in Q1 2014 was Baupost Group, an estimated $95.2M added.
  • The largest Keryx Biopharmaceuticals Inc seller in Q1 2014 was Cormorant Asset Management, an estimated $22M sold.

Based on aggregated 13F filings for Q1 2014.